About this Journal Submit a Manuscript Table of Contents
Scientifica
Volume 2013 (2013), Article ID 857519, 19 pages
http://dx.doi.org/10.1155/2013/857519
Review Article

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, Room 555, Pittsburgh, PA 15232, USA

Received 6 December 2012; Accepted 10 January 2013

Academic Editors: D. Jun and M. H. Manjili

Copyright © 2013 Ahmad Tarhini. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [35 citations]

The following is the list of published articles that have cited the current article.

  • Brian A. Baldo, “Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses,” Oncoimmunology, vol. 2, no. 10, 2013. View at Publisher · View at Google Scholar
  • Ahmad A. Tarhini, Howard Edington, Lisa H. Butterfield, Yan Lin, Yongli Shuai, Hussein Tawbi, Cindy Sander, Yan Yin, Matthew Holtzman, Jonas Johnson, Uma N. M. Rao, and John M. Kirkwood, “Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab,” Plos One, vol. 9, no. 2, 2014. View at Publisher · View at Google Scholar
  • Lawrence Steinman, “Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease,” European Journal of Immunology, vol. 44, no. 11, pp. 3201–3205, 2014. View at Publisher · View at Google Scholar
  • Rajasekharan Somasundaram, and Meenhard Herlyn, “Nivolumab in combination with ipilimumab for the treatment of melanoma,” Expert Review of Anticancer Therapy, vol. 15, no. 10, pp. 1135–1141, 2015. View at Publisher · View at Google Scholar
  • Lieping Chen, and Xue Han, “Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future,” Journal Of Clinical Investigation, vol. 125, no. 9, pp. 3384–3391, 2015. View at Publisher · View at Google Scholar
  • Anne Bertrand, Marie Kostine, Thomas Barnetche, Marie-Elise Truchetet, and Thierry Schaeverbeke, “Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis,” BMC Medicine, vol. 13, no. 1, 2015. View at Publisher · View at Google Scholar
  • David Hogg, Anthony M. Joshua, Leila Khoja, Marcus Ortho Butler, and Mary Anne Chappell, “Increased treatment-related toxicity subsequent to an anti-PD-1 agent,” Current Oncology, vol. 22, no. 4, pp. E320–E322, 2015. View at Publisher · View at Google Scholar
  • Kara M. De Felice, Arjun Gupta, Sagar Rakshit, Sahil Khanna, Lisa A. Kottschade, Heidi D. Finnes, Konstantinos A. Papadakis, Edward V. Loftus, Laura E. Raffals, and Svetomir N. Markovic, “Ipilimumab-induced colitis in patients with metastatic melanoma,” Melanoma Research, vol. 25, no. 4, pp. 321–327, 2015. View at Publisher · View at Google Scholar
  • Shannon K. Quirk, Anna K. Shure, and Devendra K. Agrawal, “Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma,” Translational Research, 2015. View at Publisher · View at Google Scholar
  • P. B. Araujo, M. C. A. Coelho, M. Arruda, M. R. Gadelha, and L. V. Neto, “Ipilimumab-induced hypophysitis: review of the literature,” Journal of Endocrinological Investigation, 2015. View at Publisher · View at Google Scholar
  • Stephanie A. Howard, Michael H. Rosenthal, Jyothi P. Jagannathan, Katherine M. Krajewski, Atul B. Shinagare, Nikhil H. Ramaiya, and Sree Harsha Tirumani, “Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology,” American Journal Of Roentgenology, vol. 204, no. 5, pp. 919–932, 2015. View at Publisher · View at Google Scholar
  • A Covre, S Coral, H Nicolay, G Parisi, C Fazio, F Colizzi, E Fratta, A M Di Giacomo, L Sigalotti, P G Natali, and M Maio, “Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models,” OncoImmunology, vol. 4, no. 8, pp. e1019978, 2015. View at Publisher · View at Google Scholar
  • Crescens Tiu, Carmel Pezaro, Ian D Davis, Mathis Grossmann, and Phillip Parente, “Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management,” Asia-Pacific Journal of Clinical Oncology, 2015. View at Publisher · View at Google Scholar
  • Gwilym J. Webb, and David H. Adams, “Modeling idiosyncrasy: A novel animal model of drug-induced liver injury,” Hepatology, 2015. View at Publisher · View at Google Scholar
  • Evangelia Papavasileiou, Sashank Prasad, Suzanne K. Freitag, Lucia Sobrin, and Ann-Marie Lobo, “Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature,” Ocular Immunology & Inflammation, pp. 1–7, 2015. View at Publisher · View at Google Scholar
  • S. Martin, A. M. Dudek-Peric, H. Maes, A. D. Garg, M. Gabrysiak, S. Demirsoy, J. V. Swinnen, and P. Agostinis, “Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells,” Biochemical Pharmacology, vol. 93, no. 3, pp. 290–304, 2015. View at Publisher · View at Google Scholar
  • Krista Rubin, “Understanding Immune Checkpoint Inhibitors for Effective Patient Care,” Clinical Journal of Oncology Nursing, vol. 19, no. 6, pp. 709–717, 2015. View at Publisher · View at Google Scholar
  • A. Sahuquillo-Torralba, R. Ballester-Sánchez, C. Pujol-Marco, and R. Botella-Estrada, “Pembrolizumab, un nuevo fármaco capaz de inducir un brote psoriasis,” Actas Dermo-Sifiliográficas, 2015. View at Publisher · View at Google Scholar
  • Sree Harsha Tirumani, Nikhil H. Ramaiya, Abhishek Keraliya, Nancy D. Bailey, Patrick A. Ott, F. Stephen Hodi, and Mizuki Nishino, “Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab,” Cancer Immunology Research, vol. 3, no. 10, pp. 1185–1192, 2015. View at Publisher · View at Google Scholar
  • J. Gao, Q. He, S. Subudhi, A. Aparicio, A. Zurita-Saavedra, D. H. Lee, C. Jimenez, M. Suarez-Almazor, and P. Sharma, “Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience,” Oncogene, vol. 34, no. 43, pp. 5411–5417, 2015. View at Publisher · View at Google Scholar
  • Anja Derer, Lisa Deloch, Yvonne Rubner, Rainer Fietkau, Benjamin Frey, and Udo S. Gaipl, “Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications,” Frontiers in Immunology, vol. 6, 2015. View at Publisher · View at Google Scholar
  • Chintan H. Kapadia, Jillian L. Perry, Shaomin Tian, J. Christopher Luft, and Joseph M. DeSimone, “Nanoparticulate immunotherapy for cancer,” Journal of Controlled Release, 2015. View at Publisher · View at Google Scholar
  • T. Stahl, and C. Loquai, “Therapienebenwirkungen und Nachsorge bei malignem Melanom,” Der Radiologe, 2015. View at Publisher · View at Google Scholar
  • Magalie P. Tardy, Lauris Gastaud, Annick Boscagli, Frederic Peyrade, Andrea Gallamini, and Antoine Thyss, “Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report,” Hematological Oncology, 2016. View at Publisher · View at Google Scholar
  • Jennifer Peterson, and Susan Steele-Moses, “Update on New Therapies With Immune Checkpoint Inhibitors,” Clinical Journal of Oncology Nursing, vol. 20, no. 4, pp. 405–410, 2016. View at Publisher · View at Google Scholar
  • Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, and Kirsten D. Mertz, “Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy,” Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 2016. View at Publisher · View at Google Scholar
  • Shane Mesko, Gottfried E Konecny, Paul C Tumeh, and Mitchell Kamrava, “Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review,” BJR|case reports, pp. 20160002, 2016. View at Publisher · View at Google Scholar
  • Simon Pernot, Toulsie Ramtohul, and Julien Taieb, “Checkpoint inhibitors and gastrointestinal immune-related adverse events,” Current Opinion in Oncology, vol. 28, no. 4, pp. 264–268, 2016. View at Publisher · View at Google Scholar
  • Joëlle Antoun, Cherif Titah, and Isabelle Cochereau, “Ocular and orbital side-effects of checkpoint inhibitors,” Current Opinion in Oncology, vol. 28, no. 4, pp. 288–294, 2016. View at Publisher · View at Google Scholar
  • F. C. Fierz, F. Meier, K. Chaloupka, and C. Boeni, “Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma - Case Series and Review,” Klinische Monatsblatter Fur Augenheilkunde, vol. 233, no. 4, pp. 540–544, 2016. View at Publisher · View at Google Scholar
  • N. Stjepanovic, J. P. Velazquez-Martin, and P. L. Bedard, “Ocular toxicities of MEK inhibitors and other targeted therapies,” Annals of Oncology, vol. 27, no. 6, pp. 998–1005, 2016. View at Publisher · View at Google Scholar
  • Baofu Zhang, Weina Zhao, Huizhong Li, Yuanyuan Chen, Hui Tian, Liantao Li, Longzhen Zhang, Chao Gao, and Junnian Zheng, “Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155,” Cancer Immunology, Immunotherapy, 2016. View at Publisher · View at Google Scholar
  • A. Sahuquillo-Torralba, R. Ballester-Sánchez, C. Pujol-Marco, and R. Botella-Estrada, “Pembrolizumab: a New Drug That Can Induce Exacerbations of Psoriasis,” Actas Dermo-Sifiliográficas (English Edition), 2016. View at Publisher · View at Google Scholar
  • Leila Khoja, Eshetu G. Atenafu, Qian Ye, Craig Gedye, Maryanne Chappell, David Hogg, Marcus O. Butler, and Anthony M. Joshua, “Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma,” Oncology Letters, vol. 11, no. 2, pp. 1581–1585, 2016. View at Publisher · View at Google Scholar
  • Adam Brys, Raghavendra Gowda, Daniel Loriaux, Gavin P. Robertson, and Paul J. Mosca, “Nanotechnology-Based Strategies for Combating Toxicity and Resistance in Melanoma Therapy,” Biotechnology Advances, 2016. View at Publisher · View at Google Scholar